GSK bets big with Tesaro buy

Dec 03, 2018

 GlaxoSmithKline has agreed to buy cancer biotech, Tesaro, for $5.1B.

Massachusetts-based Tesaro makes ovarian cancer drug, Zejula, which belongs to a class of cancer drugs called PARP inhibitors.

According to GSK, PARP inhibitors offer significant opportunities for use in the treatment of multiple cancer types. In addition to ovarian cancer, Zejula is currently being investigated for use as a possible treatment in lung, breast and prostate cancer, both as a monotherapy and in combination with other medicines.

As GSK works to refresh its R&D strategy, the Tesaro buy is its first big acquisition since pharma veteran Hal Barron joined as its chief scientific officer.

Read the press release

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments